1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1275 articles with Genentech, Inc.
Genentech announced positive topline results from its Phase III PEMPHIX trial evaluating Rituxan (rituximab) compared to the immunosuppressant drug mycophenolate mofetil in patients with pemphigus vulgaris.
FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application and granted Priority Review for the use of Rituxan®, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children two years of age and older.
Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
Genentech, a member of the Roche Group, announced positive topline results for NOBILITY, a Phase II clinical trial investigating the safety and efficacy of Gazyva® for adults with proliferative lupus nephritis.
Data from the clinical study showed that 40% of people treated with the Polivy regimen achieved a complete response.
Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Genentech announced that the Phase III BLOCKSTONE study, conducted by Shionogi & Co., Ltd., met its primary endpoint showing that people exposed to a household member with influenza and treated preventatively with XOFLUZA™ were significantly less likely to develop the disease compared to those treated with placebo.
Pivotal Phase III CLL14 Results for Venclexta in Combination with Gazyva for Chronic Lymphocytic Leukemia Presented at ASCO 2019 and Published in the New England Journal of Medicine
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the pivotal Phase III CLL14 study in previously untreated chronic lymphocytic leukemia (CLL) showing that Venclexta® (venetoclax) plus Gazyva® (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival (PFS).
Xofluza showed a significant preventive effect after a single oral dose. Only about 1.9% of patients who received Xofluza showed signs of the flu, compared to 13.6% of the placebo group.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
Corrona, LLC is pleased to announce a key milestone for the Corrona® Multiple Sclerosis Registry, a real-world US-based registry developed as a collaborative effort with the National MS Society.
Parvus Therapeutics Enters into Worldwide Collaboration and License Agreement with Genentech to Develop Navacim™ Therapeutics for the Treatment of Autoimmune Diseases
Parvus Eligible to Receive Upfront and Milestone Payments Exceeding $800 Million Plus Royalties on Net Sales
Financial terms of the deal were not disclosed, but Genentech aims to use Parvus' technology to target IBD and Celiac.
The combination of Venclexta and Gazyva was rapidly approved by the FDA under a pilot program.
Genentech’s Personalized Medicine Entrectinib Shrank Tumors Harboring NTRK, ROS1 or ALK Gene Fusions in Children and Adolescents
Genentech’s Personalized Medicine Entrectinib Shrank Tumors Harboring NTRK, ROS1 or ALK Gene Fusions in Children and Adolescents – Phase I/II study of entrectinib, an investigational medicine, showed responses in all pediatric tumor types harboring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) fusions, including those in the central nervous system – – Data
Genentech Announces FDA Approval for Venclexta Plus Gazyva for People With Previously Untreated Chronic Lymphocytic Leukemia
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Venclexta® (venetoclax) in combination with Gazyva® (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting
In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease
Genentech, a Roche company, presented data from its FIREFISH clinical trial of risdiplam in Type 1 spinal muscular atrophy (SMA) at the American Academy of Neurology Annual Meeting.
The FDA rapidly reviewed and approved the medication under the FDA’s Real-Time Oncology Review (RTOR) and Assessment Aid pilot program.